Darmstadt, Germany (ots/PRNewswire) - - Efficacy and safety data support positive benefit/risk assessment from CHMP - Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical ...
Darmstadt, Germany (ots/PRNewswire) - - Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives - Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Merck, a leading science and technology company, honors World MS Day 2017 by announcing a ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or U.S.-based media ASCO Abstract # M7824 (anti-PD-L1/TGF-ß trap): 3006; Avelumab: 9086, 9530, 9557, 4528, 3059, 5037, e21070, e21065, e20581; Tepotinib: 4087, 8547, e15676, 20541; M3814 (DNA-PK): 2556, e14048; M7583 (BTKi): e14101 - ASCO data highlights ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - A total of 13 abstracts across seven hard-to-treat cancers highlight the progress of avelumab as a monotherapy and potential novel combination treatment option - New data in metastatic Merkel cell carcinoma and ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. and UK based media - With this approval, Pergoveris® becomes the first product with a combination of FSH and LH hormones in a ready-to-use liquid version - The new pre-filled injection device for self-administration increases ease-of-use for patients ...
Darmstadt, Germany, and New York (ots/PRNewswire) - - Second approval for BAVENCIO in less than two months - Advanced urothelial carcinoma is an aggressive disease with a high rate of recurrence Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection for the treatment of patients with ...
Darmstadt, Germany (ots/PRNewswire) - - Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo Merck, a leading science and technology company, announced the presentation of new analyses of efficacy and safety data for investigational Cladribine Tablets in ...
Darmstadt, Germany (ots/PRNewswire) - - Breadth of data and activities underscore company's long-standing commitment to enhancing care for people with MS Merck, a leading science and technology company, will present data at the American Academy of Neurology (AAN) 69th Annual Meeting, taking place from April 22-28, ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Only FDA-approved treatment for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer - First indication for BAVENCIO, a human anti-PD-L1 antibody Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and ...
Darmstadt, Germany (ots/PRNewswire) - - Merck integrates innovative Eeva® Test with Geri(TM) incubation platform, bringing individualized incubation and outcome prediction together - Geri(TM) humidity technology aims to further advance incubation to precisely monitor and manage the humidity level in the incubator Merck, a leading science and technology company, today ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - More patients now able to receive a standard-of-care treatment with Erbitux plus FOLFIRI or FOLFOX - NICE's recommendation is a significant step forward in Merck's aspiration to ensure cancer patients have optimal access to effective ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US and UK-based media - Second Biologics License Application accepted by the FDA for avelumab - Prognosis for urothelial carcinoma is currently poor, particularly when the disease has metastasized Merck and Pfizer Inc. today announced that the US ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. and UK based media - Ready-to-use pre-filled pen provides a convenient treatment option for patients - Simplified injection device for self-administration comes in multiple doses, addressing individual needs of patients Merck, a leading science and technology company, today announced that the European ...
Darmstadt (ots) - Annual 400,000 people deficit threatens the UK's housing and infrastructure delivery - Failure to tackle labour shortfall could give rise to UK's MINTED workforce - Most in Need Trades Earning Double - UK could miss out on an additional 215,000 migrant workers by 2020 in event of 'hard' Brexit British construction must recruit over 400,000 people each ...
Darmstadt, Germany (ots/PRNewswire) - - Post hoc analysis of Phase III CLARITY study data recently published in Multiple Sclerosis Journal showed statistically significant reduction in brain atrophy in patients on a short course of investigational Cladribine Tablets over two years compared with patients receiving placebo - These findings correlated with effects on ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Merck is broadening its efforts to support ART clinics to achieve excellence for patients - Through leading edge education and training, the Centre of Excellence aims to support clinics to achieve consistent and high level of outcome Merck, a leading science and technology company, today announced the opening of its first Centre of Excellence (CoE) ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved by the FDA, avelumab, an investigational immunotherapy, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma (MCC) - Avelumab has previously received FDA Breakthrough Therapy and Fast ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Grant established by Merck KGaA, Darmstadt, Germany, recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck KGaA, ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or UK-based media - Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck, a leading science and technology company, today announced the recipients of ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media ESMO Abstract # Avelumab: 777PD, 7775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck KGaA, Darmstadt, Germany, to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ESMO Abstract # Avelumab: 777PD, 775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P, 1287TiP, 1292TiP - Merck to feature new research from marketed and pipeline compounds - Preliminary results from combination study with avelumab in renal cell carcinoma, and ...
Darmstadt, Germany (ots/PRNewswire) - - New partnership under Healthy Women, Healthy Economies initiative facilitates women to overcome health barriers to economic participation Merck, a leading science and technology company, today announced its partnership with the Royal Health Awareness Society (RHAS) of Jordan to advance health awareness and education particularly ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with Cladribine Tablets Merck, a leading science and technology company, announced they ...
Darmstadt, Germany (ots/PRNewswire) - - Four research grants awarded out of 260 proposals from 45 countries Merck, a leading science and technology company, today announced recipients of the fourth annual Grant for Multiple Sclerosis Innovation (GMSI) during a symposium at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...
Darmstadt, Germany (ots/PRNewswire) - - Two oral presentations and nine posters include new analyses on investigational Cladribine Tablets - Real-world data assess the safety, tolerability and effectiveness of Rebif® - Symposium highlights unmet needs among patients with MS and real-word issues - Grant for Multiple ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 - Merck is the first pharmaceutical company to collaborate with multiple diagnostic providers to support liquid biopsy RAS biomarker testing worldwide ...
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...
Darmstadt, Germany (ots/PRNewswire) - - Agreement provides Merck with exclusive license to cognitive remediation training programs - HAPPYneuron will be available for inclusion in Merck's MSdialog platform for use with Rebif® (interferon beta-1a) Merck, a leading science and technology company, announced today that ...